



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾										
<u>BABY CARE</u>										
US	105	99	6.1%	6.1%	-	210	202	4.0%	4.0%	-
Intl	493	438	12.6%	5.0%	7.6%	949	864	9.8%	4.1%	5.7%
WW	598	537	11.4%	5.2%	6.2%	1,159	1,066	8.7%	4.1%	4.6%
<u>ORAL CARE</u>										
US	158	148	6.8%	6.8%	-	321	322	-0.3%	-0.3%	-
Intl	241	224	7.6%	-2.1%	9.7%	469	431	8.8%	1.6%	7.2%
WW	399	372	7.3%	1.5%	5.8%	790	753	4.9%	0.8%	4.1%
<u>OTC/NUTRITIONALS</u>										
US	330	492	-32.9%	-32.9%	-	727	1,034	-29.7%	-29.7%	-
Intl	753	649	16.0%	4.8%	11.2%	1,485	1,314	13.0%	5.8%	7.2%
WW	1,083	1,141	-5.1%	-11.5%	6.4%	2,212	2,348	-5.8%	-9.8%	4.0%
<u>SKIN CARE</u>										
US	449	422	6.4%	6.4%	-	875	874	0.1%	0.1%	-
Intl	480	421	14.0%	4.3%	9.7%	953	889	7.2%	1.1%	6.1%
WW	929	843	10.2%	5.3%	4.9%	1,828	1,763	3.7%	0.6%	3.1%
<u>WOMEN'S HEALTH</u>										
US	121	137	-11.7%	-11.7%	-	246	283	-13.1%	-13.1%	-
Intl	356	329	8.2%	-0.9%	9.1%	690	652	5.8%	-0.1%	5.9%
WW	477	466	2.4%	-4.0%	6.4%	936	935	0.1%	-4.0%	4.1%
<u>WOUND CARE/OTHER</u>										
US	176	165	6.7%	6.7%	-	305	308	-1.0%	-1.0%	-
Intl	131	123	6.5%	-3.3%	9.8%	245	240	2.1%	-4.6%	6.7%
WW	307	288	6.6%	2.8%	3.8%	550	548	0.4%	-2.7%	3.1%
<u>TOTAL CONSUMER</u>										
US	1,339	1,463	-8.5%	-8.5%	-	2,684	3,023	-11.2%	-11.2%	-
Intl	2,454	2,184	12.4%	2.8%	9.6%	4,791	4,390	9.1%	2.6%	6.5%
WW	3,793	3,647	4.0%	-1.8%	5.8%	7,475	7,413	0.8%	-3.0%	3.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational⁽¹⁾	Currency			Reported	Operational⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT⁽²⁾⁽⁴⁾										
ACIPHEX/PARIET										
US	101	121	-16.5%	-16.5%	-	210	240	-12.5%	-12.5%	-
Intl	146	133	9.8%	-2.7%	12.5%	276	274	0.7%	-5.9%	6.6%
WW	247	254	-2.8%	-9.4%	6.6%	486	514	-5.4%	-8.9%	3.5%
CONCERTA/METHYLPHENIDATE										
US	234	223	4.9%	4.9%	-	488	454	7.5%	7.5%	-
Intl	115	100	15.0%	3.6%	11.4%	223	198	12.6%	4.9%	7.7%
WW	349	323	8.0%	4.5%	3.5%	711	652	9.0%	6.7%	2.3%
DOXIL/CAELYX										
US	56	78	-28.2%	-28.2%	-	120	150	-20.0%	-20.0%	-
Intl	82	10	*	*	11.0%	157	18	*	*	7.0%
WW	138	88	56.8%	50.3%	6.5%	277	168	64.9%	60.9%	4.0%
DURAGESIC/FENTANYL TRANSDERMAL										
US	34	37	-8.1%	-8.1%	-	38	75	-49.3%	-49.3%	-
Intl	133	147	-9.5%	-19.8%	10.3%	256	293	-12.6%	-19.3%	6.7%
WW	167	184	-9.2%	-17.4%	8.2%	294	368	-20.1%	-25.4%	5.3%
LEVAQUIN/FLOXIN										
US	149	289	-48.4%	-48.4%	-	571	652	-12.4%	-12.4%	-
Intl	10	11	-9.1%	-13.3%	4.2%	22	19	15.8%	11.0%	4.8%
WW	159	300	-47.0%	-47.2%	0.2%	593	671	-11.6%	-11.7%	0.1%
PREZISTA										
US	128	99	29.3%	29.3%	-	254	188	35.1%	35.1%	-
Intl	185	105	76.2%	65.9%	10.3%	325	203	60.1%	54.3%	5.8%
WW	313	204	53.4%	47.3%	6.1%	579	391	48.1%	44.8%	3.3%
PROCRIPT/EPREX										
US	257	306	-16.0%	-16.0%	-	447	596	-25.0%	-25.0%	-
Intl	218	220	-0.9%	-11.2%	10.3%	425	453	-6.2%	-11.8%	5.6%
WW	475	526	-9.7%	-14.0%	4.3%	872	1,049	-16.9%	-19.3%	2.4%
REMICADE										
US	836	783	6.8%	6.8%	-	1,624	1,563	3.9%	3.9%	-
US Exports ⁽³⁾	527	341	54.5%	54.5%	-	1,017	741	37.2%	37.2%	-
Intl	8	6	33.3%	33.3%	0.0%	15	12	25.0%	25.0%	0.0%
WW	1,371	1,130	21.3%	21.3%	0.0%	2,656	2,316	14.7%	14.7%	0.0%
RISPERDAL/RISPERIDONE										
US	11	(17)	-	-	-	19	(12)	-	-	-
Intl	128	134	-4.5%	-14.1%	9.6%	247	267	-7.5%	-14.4%	6.9%
WW	139	117	18.8%	7.8%	11.0%	266	255	4.3%	-3.0%	7.3%
RISPERDAL CONSTA										
US	110	115	-4.3%	-4.3%	-	224	232	-3.4%	-3.4%	-
Intl	294	240	22.5%	8.7%	13.8%	584	502	16.3%	8.9%	7.4%
WW	404	355	13.8%	4.5%	9.3%	808	734	10.1%	5.0%	5.1%
TOPAMAX										
US	41	59	-30.5%	-30.5%	-	91	116	-21.6%	-21.6%	-
Intl	80	83	-3.6%	-13.2%	9.6%	159	174	-8.6%	-13.8%	5.2%
WW	121	142	-14.8%	-20.4%	5.6%	250	290	-13.8%	-16.9%	3.1%
VELCADE										
US	-	-	-	-	-	-	-	-	-	-
Intl	347	286	21.3%	10.0%	11.3%	627	547	14.6%	7.9%	6.7%
WW	347	286	21.3%	10.0%	11.3%	627	547	14.6%	7.9%	6.7%
OTHER										
US	755	676	11.7%	11.7%	-	1,527	1,321	15.6%	15.6%	-
Intl	1,248	968	28.9%	17.6%	11.3%	2,346	1,915	22.5%	15.2%	7.3%
WW	2,003	1,644	21.8%	15.2%	6.6%	3,873	3,236	19.7%	15.4%	4.3%
TOTAL PHARMACEUTICAL										
US	3,239	3,110	4.1%	4.1%	-	6,630	6,316	5.0%	5.0%	-
Intl	2,994	2,443	22.6%	10.7%	11.9%	5,662	4,875	16.1%	8.9%	7.2%
WW	6,233	5,553	12.2%	7.0%	5.2%	12,292	11,191	9.8%	6.7%	3.1%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MAJOR NEW PHARM PRODUCTS ⁽⁴⁾
(INCLUDED IN OTHER)

INTELENCE

	SECOND QUARTER		
	2011	2010	Total % Change
US	38	32	18.8%
Intl	41	24	70.8%
WW	79	56	41.1%

INVEGA

	SECOND QUARTER		
	2011	2010	Total % Change
US	76	68	11.8%
Intl	52	34	52.9%
WW	128	102	25.5%

SIMPONI

	SECOND QUARTER		
	2011	2010	Total % Change
US	61	47	29.8%
Intl	6	12	-50.0%
WW	67	59	13.6%

STELARA

	SECOND QUARTER		
	2011	2010	Total % Change
US	100	49	104.1%
Intl	76	37	105.4%
WW	176	86	104.7%

	SIX MONTHS		
	2011	2010	Total % Change
INTELENCE	76	63	20.6%
INTELENCE	72	48	50.0%
INTELENCE	148	111	33.3%
INVEGA	145	137	5.8%
INVEGA	103	73	41.1%
INVEGA	248	210	18.1%
SIMPONI	114	86	32.6%
SIMPONI	48	15	220.0%
SIMPONI	162	101	60.4%
STELARA	205	105	95.2%
STELARA	137	68	101.5%
STELARA	342	173	97.7%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational⁽¹⁾	Currency			Reported	Operational⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS⁽²⁾										
CARDIOVASCULAR CARE⁽⁵⁾										
US	210	265	-20.8%	-20.8%	-	452	516	-12.4%	-12.4%	-
Intl	377	390	-3.3%	-12.9%	9.6%	770	811	-5.1%	-11.4%	6.3%
WW	587	655	-10.4%	-16.1%	5.7%	1,222	1,327	-7.9%	-11.7%	3.8%
DEPUY										
US	770	776	-0.8%	-0.8%	-	1,581	1,590	-0.6%	-0.6%	-
Intl	699	599	16.7%	4.0%	12.7%	1,391	1,239	12.3%	4.2%	8.1%
WW	1,469	1,375	6.8%	1.3%	5.5%	2,972	2,829	5.1%	1.5%	3.6%
DIABETES CARE										
US	333	313	6.4%	6.4%	-	644	603	6.8%	6.8%	-
Intl	348	303	14.9%	4.1%	10.8%	674	610	10.5%	4.5%	6.0%
WW	681	616	10.6%	5.3%	5.3%	1,318	1,213	8.7%	5.7%	3.0%
ETHICON										
US	540	509	6.1%	6.1%	-	1,056	1,019	3.6%	3.6%	-
Intl	717	623	15.1%	4.2%	10.9%	1,394	1,260	10.6%	3.7%	6.9%
WW	1,257	1,132	11.0%	5.0%	6.0%	2,450	2,279	7.5%	3.7%	3.8%
ETHICON ENDO-SURGERY										
US	490	507	-3.4%	-3.4%	-	961	990	-2.9%	-2.9%	-
Intl	805	689	16.8%	5.5%	11.3%	1,555	1,374	13.2%	5.8%	7.4%
WW	1,295	1,196	8.3%	1.8%	6.5%	2,516	2,364	6.4%	2.1%	4.3%
ORTHO-CLINICAL DIAGNOSTICS										
US	281	264	6.4%	6.4%	-	546	552	-1.1%	-1.1%	-
Intl	269	230	17.0%	6.4%	10.6%	525	467	12.4%	5.2%	7.2%
WW	550	494	11.3%	6.4%	4.9%	1,071	1,019	5.1%	1.8%	3.3%
VISION CARE										
US	245	232	5.6%	5.6%	-	501	481	4.2%	4.2%	-
Intl	487	430	13.3%	2.1%	11.2%	953	845	12.8%	4.0%	8.8%
WW	732	662	10.6%	3.3%	7.3%	1,454	1,326	9.7%	4.1%	5.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	2,869	2,865	0.1%	0.1%	-	5,741	5,751	-0.2%	-0.2%	-
Intl	3,702	3,265	13.4%	2.2%	11.2%	7,262	6,606	9.9%	2.5%	7.4%
WW	6,571	6,130	7.2%	1.3%	5.9%	13,003	12,357	5.2%	1.3%	3.9%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Previously Cordis